Main Menu

Professor Manuel Salto-Tellez

Team Leader

The alt text
Professor Manuel Salto-Tellez is a recognised international leader in molecular and digital pathology. His research focus is on the relationship of phenotype to genotype, with a specific interest in the pathway of cancer biomarker development from discovery to clinical adoption. Team: Integrated Pathology
+44 20 3437 6056 ORCID 0000-0001-8586-282X

Biography

 

Professor Manuel Salto-Tellez (MD-LMS, FRCPath, FRCPI) is the Professor of Integrative Pathology at The Institute for Cancer Research, London, and the lead of Joint Integrated Pathology Unit at The Institute of Cancer Research (ICR) and The Royal Marsden NHS Foundation Trust. He is also the Chair of Molecular Pathology at Queen’s University Belfast (QUB), a clinical consultant pathologist and the Lead of QUB’s Precision Medicine Centre of Excellence.

Manuel studied Medicine in Spain (Oviedo), Germany (Aachen) and The Netherlands (Leiden). He specialized in Histopathology in the UK (Edinburgh and London) and in Molecular Pathology in USA (Philadelphia). For more than 10 years he worked at the National University of Singapore and its National University Hospital, where he was associate professor, senior consultant, director of the Diagnostic Molecular Oncology Centre, Vice-dean for Research and senior scientist at the Cancer Research Institute.

Professor Salto-Tellez is author or co-author of more than 320 internationally peer-reviewed articles in translational science, molecular pathology and diagnostics, has published a similar number of abstracts in international conferences, and is editor or contributor to some of the key textbooks of pathology and oncology. Manuel holds more than £21M in competitive grant funding. He is scientific advisor to two companies in the digital pathology and artificial intelligence space.

Manuel's research activity has always been at the interface of phenotype and genotype – allowing the application of genomic analysis, digital pathology & artificial intelligence, and integrated diagnostics in creating a new generation of complex, meaningful biomarkers in cancer. Manuel’s integrated model of research cuts across technologies and cancer types, taking the clinical/diagnostic need as the key research focus. His advocacy and work on digital pathology and morpho-molecular diagnostics across the UK, Europe and the USA has helped to shape modern pathology.

Since he joined the ICR and The Royal Marsden, Manuel has established the Joint Integrated Pathology Unit as “England’s first centre aiming to develop complex tissue hybridization and computer analysis systematically applied to clinical trials”; co-led the Integrated Diagnostics and Discovery programme between the ICR and The Royal Marsden; and championed the digitization of the histopathology services in The Royal Marsden, with a provision for access of those images for research purposes.